Journal of Political Economy Microeconomics · 2024 · Kevin Callison、Michael Darden、Keith Teltser
中文摘要
我们评估了直接抗病毒药物 (DAA) 疗法治疗丙型肝炎 (HCV) 的引入对美国肝移植分配的影响。我们假设 DAA 使部分 HCV 阳性患者不再需要移植，从而可能使 HCV 阴性登记者受益，并诱使边缘性 HCV 阴性患者登记。我们发现，2014 年至 2019 年间，DAA 的可及性使 HCV 阴性肝病患者额外获得了 5,682 例肝移植，产生了 75.2 亿美元的正外部性。此外，我们还发现 HCV 阴性等待名单登记数年均增长 37%。若不存在这一行为反应，DAA 疗法本可彻底消除肝移植等待名单。
Abstract
We evaluate the introduction of direct-acting antiviral (DAA) therapy for hepatitis C (HCV) on liver transplant allocation in the United States. We hypothesize that DAAs obviate the need for transplant for some HCV-positive patients, potentially benefiting HCV-negative registrants and inducing marginal HCV-negative patients to register. We find that DAA availability resulted in an additional 5,682 liver transplants to HCV-negative liver disease patients between 2014 and 2019, generating a positive externality of $7.52 billion. Furthermore, we show a 37% average annual increase in HCV-negative waiting list registrations. Without this behavioral response, DAA therapies would have eliminated the liver transplant waiting list.